The vast majority of people with epilepsy are overwhelmingly treated with no knowledge of their genomic makeup. However, the future of medicine would seem to lie in the ability to more accurately target epilepsy treatment based upon knowledge of a person’s genome. This is commonly referred to as precision medicine, personalised medicine, or genomic medicine.

As a Genome Scientist, I have spent my career working on the human genome. I am also the parent of two young children who, unfortunately, both suffered brain damage during birth and have severe cerebral palsy. My daughter also developed a rare and catastrophic form of epilepsy at 8 months, called West syndrome, or infantile spasms.

When scientists and clinicians write research papers, we have to do it in a very particular way, using technical words and following strict ways of working. However, this isn’t particularly helpful for most people with epilepsy who want to read about the research into their condition, but don’t necessarily know all of the technical terms!

It is estimated that 1 in around 200,000 people is born with a hypothalamic hamartoma (HH), an epileptogenic lesion attached to the hypothalamus. However, HH syndrome is so rare

First and foremost, I am mum to my 18-year-old twins, Will and Ella. Will has had seizures since day 4 of his life and it wasn’t until he was 14 that we found out that he had a rare genetic epilepsy called SCN2A2. I’m also Founder of SCN2A Australia3, Co-Founder of Genetic Epilepsy Team Australia (GETA)4, and on the Leadership Council for Global Genes5.

Previously Charlie’s paediatricians had diagnosed childhood autism and ADHD. It was only when I read up about odd bursts of laughter and discovered gelastic epilepsy that I was able to insist upon an MRI scan which revealed his hypothalamic hamartoma.